Obesity drugs stocks
비만치료제
What are Obesity drugs stocks in Korea?
The Obesity drugs theme on jonbur groups 12 Korean stocks listed on KOSPI and KOSDAQ, worth ₩23T in total. On Oct 27, 2026 the group moved down 1.44% (weighted by market value); the largest members are Yuhan, Hanmi Pharm, SAM Chun Dang Pharm.
Key facts
- Stocks
- 12
- Total market value
- ₩23T
- Day's move
- −1.44%
- As of
- Oct 27, 2026
- Largest members
- Yuhan, Hanmi Pharm, SAM Chun Dang Pharm
Earnings tracker · 3Q 2026
Reporting season · reports due by Nov 14
Combined, for the companies that have reported, vs the same quarter a year ago
| Company | Reported | Revenue | vs a year ago | Operating profit | vs a year ago | vs last quarter | Op. margin |
|---|---|---|---|---|---|---|---|
| Hanmi Pharm | Oct 27Preliminary | ₩377B | +4.2% | ₩38B | −31.3% | −71.2% | 10.0%15.2% |
| Dong-A ST | Oct 27Preliminary | ₩207B | −4.4% | ₩21B | +52.9% | +239.9% | 10.4%6.5% |
| HK inno.N | Expected around Oct 29 | ||||||
| Yuhan | Expected around Nov 5 | ||||||
| IL Dong Pharmaceutical | Expected around Nov 6 | ||||||
| Daewoong Pharma | Expected around Nov 7 | ||||||
| G2GBIO | Expected around Nov 13 | ||||||
| SAM Chun Dang Pharm | Expected around Nov 14 | ||||||
| Peptron | Expected around Nov 14 | ||||||
| D&D Pharmatech | Expected around Nov 14 | ||||||
| Raphas | Expected around Nov 14 | ||||||
| Inventage Lab | Expected around Dec 1 | ||||||
Single-quarter figures. Preliminary figures are the company's own early numbers and are replaced by the quarterly report when it's filed. Expected dates are around when each company reported a year ago.
Technical breadth
After the close on Oct 27, 2026- Above 20-day average
- 25%
- Above 60-day average
- 25%
- RSI above 70
- 0%
- RSI below 30
- 16.7%
- 52-week highs
- 0
- 52-week lows
- 2
Index gauge · Short term
Bearish
0 bullish, 1 neutral, 8 bearish
Index gauge · Medium term
Bearish
0 bullish, 1 neutral, 7 bearish
Technical read
The obesity drugs theme covers 4 member stocks, and none of them currently sits above its 20-day average, while 25% are above their 60-day average. Breadth is weak on the short-term measures, with 25% of members showing RSI in the oversold zone and no members showing overbought readings. None of the members are at 52-week highs, and none are at 52-week lows. The equal-weighted member index is in a bearish short-term and medium-term state, with an RSI of 39.4 and the index trading below its cloud.
Written by AI from the indicator values above. Not advice.
Share of members, from each member's own indicators; the gauge reads an equal-weighted index of the members. Technical indicators describe past price and volume patterns. They are not predictions or recommendations.
Credit & macro
No notable credit, ELS or macro events for these companies in the last 30 days.
Obesity drugs
−1.35%비만치료제
The obesity drugs theme covers Korean companies involved in developing, manufacturing, or contract-producing medications for weight management, including GLP-1-based injectables and related peptide therapies. Korean investors group these firms together because many of them supply active ingredients, formulation technology, or contract manufacturing for global pharmaceutical developers, and because the category has drawn attention from the broader global shift toward incretin-based treatments. The theme is often discussed alongside diabetes treatments, since many obesity drugs share mechanisms and development pathways with them.
12 companies · 4 up · 0 flat · 8 down
- Traded value
- ₩145B
- Value vs 20-day average
- 0.76×
- Top gainer
- Dong-A ST +2.95%
- Largest company
- Yuhan ₩5.9T
Companies in this theme
| Company | Price | Daily | Traded value | Market cap | NPS |
|---|---|---|---|---|---|
Yuhan000100 · KOSPI | ₩80,000 | −2.08% | ₩16B | ₩5.9T | 6.83% |
Hanmi Pharm128940 · KOSPI | ₩350,500 | −0.57% | ₩26B | ₩4.5T | 9.61% |
SAM Chun Dang Pharm000250 · KOSDAQ | ₩187,600 | −0.69% | ₩19B | ₩4.4T | 1.34% |
Peptron087010 · KOSDAQ | ₩95,600 | −2.75% | ₩16B | ₩2.2T | 1.63% |
D&D Pharmatech347850 · KOSDAQ | ₩40,800 | +0.37% | ₩14B | ₩1.9T | 1.75% |
Daewoong Pharma069620 · KOSPI | ₩99,100 | −1.49% | ₩2.2B | ₩1.1T | 10.30% |
HK inno.N195940 · KOSDAQ | ₩32,750 | −0.91% | ₩2.9B | ₩928B | 5.03% |
G2GBIO456160 · KOSDAQ | ₩39,150 | −13.38% | ₩47B | ₩651B | 2.41% |
IL Dong Pharmaceutical249420 · KOSPI | ₩12,650 | +2.02% | ₩915M | ₩400B | 2.30% |
Dong-A ST170900 · KOSPI | ₩34,900 | +2.95% | ₩1.2B | ₩340B | 4.78% |
Inventage Lab389470 · KOSDAQ | ₩22,800 | −0.22% | ₩1.1B | ₩303B | 0.31% |
Raphas214260 · KOSDAQ | ₩6,950 | +0.58% | ₩16M | ₩62B | 0.90% |
Source: KRX statistical information